learn Tofacitinib
a JAK inhibitor for alopecia areata and other autoimmune conditions
Search
forLearn
5 / 801 resultslearn Baricitinib
JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases
learn Beclomethasone
learn retinoic acid
learn docosahexaenoic acid
Research
5 / 1000+ results
research Skin Lesions in a Daclizumab-treated Patient with Multiple Sclerosis
A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.
research Daclizumab
Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.
research Cutaneous Toxicities From Transplantation-Related Medications
Skin problems from transplant drugs are common and need careful management in organ transplant patients.
research Psoriatic Alopecia and Paradoxical Psoriasis Induced by Adalimumab Successfully Treated with Certolizumab: Clinical, Trichoscopic, and in vivo Reflectance Confocal Microscopy Features
Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.
research New Drugs: Eculizumab
Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.
Community Join
5 / 1000+ resultscommunity Xeljanz....the magic drug!!!
A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.
community Clascoterone full results in July
Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
community Clascoterone (Winlevi) now approved in Canada
The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.
community Clascoterone 12 months phase 3 result out
Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.
community Clascoterone (Winlevi) Update for Canada
Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.